4//SEC Filing
Aimmune Therapeutics, Inc. 4
Accession 0000899243-17-005270
CIK 0001631650operating
Filed
Feb 23, 7:00 PM ET
Accepted
Feb 24, 6:40 PM ET
Size
6.3 KB
Accession
0000899243-17-005270
Insider Transaction Report
Form 4
Knapp Jeffrey H
Chief Operating Officer
Transactions
- Award
Stock Option (right to buy)
2017-02-24+90,000→ 90,000 totalExercise: $19.63Exp: 2027-02-24→ Common Stock (90,000 underlying)
Holdings
- 2,776
Common Stock, $0.0001 par value
Footnotes (1)
- [F1]The shares subject to the option will vest and become exercisable as to one-forty-eighth (1/48th) of the total number of shares subject to the option in successive, equal monthly installments measured from February 24, 2017, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Documents
Issuer
Aimmune Therapeutics, Inc.
CIK 0001631650
Entity typeoperating
IncorporatedDE
Related Parties
1- filerCIK 0001631650
Filing Metadata
- Form type
- 4
- Filed
- Feb 23, 7:00 PM ET
- Accepted
- Feb 24, 6:40 PM ET
- Size
- 6.3 KB